Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Highlights on CAR T cells in advanced solid tumours - AACR 2022

Reporting onsite from AACR 2022 in New Orleans, John Haanen explains the results from a phase I study testing CAR T cells targeting Claudin-6 which is a protein not expressed in adult healthy tissue, but in certain ovarian, endometrial and testicular cancers. The study was carried out in patients who had previously failed all treatments. Combined with a CAR T cell amplifying RNA vaccine to prolong the CAR T cells persistence, this novel therapy showed promising early results in terms of response and safety.

Haanen J, Mackensen A, Koenecke C, et al. BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. AACR Annual Meeting 2022; New Orleans, Louisiana, USA: 8–13 April.

ESMO Members, read the Congress Watch article on this study

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.